APPROCCIO OLISTICO E PERSONALIZZATO NELLA GESTIONE DEL PAZIENTE CON UC: TREAT TO TARGET

1. 1.Akhilesh Swaminathan, MBChB, *,†,James M. Fulforth, MBChB, ‡ Chris M. Frampton, PhD, Grace M. Borichevsky, MSc, *Thomas C. Mules, MBChB, *,†,Kate Kilpatrick, MBChB,† Myriam Choukour, MSc,§ Peter Fields, MD,¶ Resham Ramkissoon, MD,¿ Emily Helms, MD,** Stephen B. Hanauer, MD,†† Rupert W. Leong, MD, **Laurent Peyrin-Biroulet, PhD,‡‡,§§,¶¶,¿¿,***,††† Corey A. Siegel, MD,‡‡‡, and Richard B. Gearry, PhD*,†. The Disease Severity Index for Inflammatory Bowel Disease Is a Valid Instrument that Predicts Complicated Disease. Inflammatory Bowel Diseases, 2023, XX, 1–12 https://doi.org/10.1093/ibd/izad294 Advance access publication 22 December 2023 Original Research Articles – Clinical. 2023
   Articolo scientificoInflammatory Bowel Diseases, 2023, XX, 1–12 https://doi.org/10.1093/ibd/izad294 Advance access publication 22 December 2023 Original Research Articles – ClinicalLeggi il PDF gratuito
2. 2.Christina Kapizioni, a,b,* Rofaida Desoki,a,c,*, Danielle Lam,a,d, Karthiha Balendran,a,e Eman Al-Sulais,a,f Sreedhar Subramanian,a Joanna E. Rimmer,g Juan De La Revilla Negro,a Holly Pavey,h,i Laetitia Pele,j,k Johanne Brooks,l,m Gordon W. Moran,n, Peter M. Irving, o,p, Jimmy K. Limdi,q.r. Christopher A. Lamb,s.t. UK IBD BioResource Investigators Miles Parkes,a Time Reine,a. Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource. Journal of Crohn's and Colitis, 2023, XX, 1–11 https://doi.org/10.1093/ecco-jcc/jjad203 Advance access publication 2 December 2023. 2023
   Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource
   LibroCerca su Amazon
3. 3.Bernd Bokemeyer 1,2,3| Sandra Plachta-Danielzik | Romina di Giuseppe 2| Philipp Efken 4| Wolfgang Mohl 5| Thomas Krause 6| Martin Hoffstadt 7| Robert Ehehalt 8| Leo Trentmann 9| Axel Schweitzer 10| Petra Jessen 11| Petra Hartmann 4| Stefan Schreiber2,3,*. Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naïve patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDOIBD-study. AP&T Alimentary Pharmacology & Therapeutics WILEY Receveid: 23 december 2022 | First decision: 23 January 2023 | Accepted: 4 June 2023 DOI: 10.1111/apt.17616. 2023
   Articolo scientificoAP&T Alimentary Pharmacology & Therapeutics WILEY Receveid: 23 december 2022 | First decision: 23 January 2023 | Accepted: 4 June 2023 DOI: 10.1111/apt.17616Leggi il PDF gratuito

I link ai libri possono contenere un codice affiliato Amazon: in qualità di affiliato, ECM Finder potrebbe ricevere una commissione sugli acquisti idonei, senza alcun costo aggiuntivo per te. I link ai paper rimandano alla fonte scientifica (DOI, versione open-access o ricerca accademica).